ライフサイエンスコーパス: antidiabetic

1 idepressants, heart failure medications, and antidiabetics.

2 rtin signaling is required for the sustained antidiabetic action of FGF1.

3 r, these findings implicate the brain in the antidiabetic action of systemic FGF19 and establish the

4 improved antioxidant, antidyslipidemic, and antidiabetic action that may serve as a potential therap

5 necessary nor sufficient to explain leptin's antidiabetic action.

6 ma glucocorticoid levels is required for its antidiabetic action.

7 ute to its capacity to lower insulinemia and antidiabetic action.

8 To investigate the potential antidiabetic actions of FGF21 in insulin-deficient Gcgr(

9 We evaluated the role and antidiabetic actions of the ERbeta selective agonist WAY

10 op improved PPARgamma modulators that retain antidiabetic actions while minimizing untoward effects.

11 potential leptin sensitizer with additional antidiabetic actions.

12 e present study deals with the evaluation of antidiabetic activities of Fagioli di Sarconi beans (Pha

13 In this study, we assessed the potential antidiabetic activities of NRTN relative to liraglutide,

14 he paradoxes among their agonistic function, antidiabetic activities, and side effects and should all

15 ents are widely consumed for their purported antidiabetic activities.

16 anticancer, antimicrobial, antioxidant, and antidiabetic activities.

17 rginal reduction (up to 10%) was observed in antidiabetic activity during storage for a period of 90

18 ave been synthesized and evaluated for their antidiabetic activity in sucrose-challenged low-dosed st

19 content (TFC), and in vitro antioxidant and antidiabetic activity of 24 plant foods of a Mayan commu

20 first report on effect of pasteurization on antidiabetic activity of bitter gourd juice.

21 lts strongly support the hypothesis that the antidiabetic activity of Cr(III) and the carcinogenicity

22 ingly, the novel proposed mechanisms for the antidiabetic activity of PPARgamma agonists, consisting

23 mic activities were also prepared, and their antidiabetic activity results indicate its association m

24 44%, while it was further evaluated for its antidiabetic activity using a type 2 diabetes experiment

25 cholinesterase activity but presented strong antidiabetic activity, in the order: 'Arbequina' approxi

26 s of different benzothiazoles with potential antidiabetic activity.

27 tidase in order to produce hydrolysates with antidiabetic activity.

28 Patients starting a third antidiabetic agent after receiving a metformin-containin

29 ile basal insulin remains the most effective antidiabetic agent and substantially reduces the risk of

30 peptidase-4 inhibitors (DPP-4is) as a third antidiabetic agent in patients with type 2 diabetes mell

31 that incorporate a structural moiety of the antidiabetic agent succinobucol.

32 Metformin is a first-line antidiabetic agent taken by 150 million people across th

33 and inhibition assays for canagliflozin, an antidiabetic agent verified its effective binding to bot

34 NAADP is thus a potential antidiabetic agent with therapeutic relevance.

35 ngiotensin-converting enzyme inhibitor, oral antidiabetic agent, calcium, and vitamin D.

36 TNFRI combined with the antidiabetic agent, metformin, improved DBD beyond that

37 ptidyl peptidase-4 inhibitor sitagliptin, an antidiabetic agent, which lowers blood glucose levels, a

38 ntroquinonol indicate that it is a potential antidiabetic agent.

39 ium, which is a proposed insulin mimetic and antidiabetic agent.

40 nstrate the importance of IF1 as a potential antidiabetic agent.

41 which supports the role of camel milk as an antidiabetic agent.

42 List prices of noninsulin antidiabetic agents (n = 10) increased by 165%, and net

43 e, I discuss a rational basis for the use of antidiabetic agents as novel and potentially effective t

44 t group) or short-acting insulin and/or oral antidiabetic agents for blood glucose >/=180-250 mg/dl (

45 y of such vanadium coordination complexes as antidiabetic agents is described.

46 ning the effects of intrauterine exposure to antidiabetic agents on longitudinal growth, and the impo

47 New antidiabetic agents show unexpected cardioprotective ben

48 T2D patients are routinely treated with oral antidiabetic agents such as sulfonylureas or dipeptidyl

49 s devoid of the side effects of the marketed antidiabetic agents thiazolidinediones and the dual agon

50 r agonists to individuals treated with other antidiabetic agents using a Cox regression with inverse

51 enosine, glucose-insulin-potassium, statins, antidiabetic agents, FX06, iron chelation, and ranolazin

52 Metabolic stress, as well as several antidiabetic agents, increases hepatic nucleotide monoph

53 In an effort to identify new antidiabetic agents, we have discovered a novel family o

54 hypoglycemia, and can be combined with other antidiabetic agents.

55 eed the in vitro activity of known synthetic antidiabetic agents.

56 ent, whereas 7 (28%) of 25 controls required antidiabetic agents.

57 R PAMs may become clinically useful as novel antidiabetic agents.

58 Medications, including antihypertensives and antidiabetics, along with dietary supplements including

59 ct of thermal pasteurization was observed on antidiabetic (alpha-amylase and alpha-glucosidase inhibi

60 e oil (EVOO) to combat several diseases, the antidiabetic and anti-cholinesterase activity of Spanish

61 oxy fatty acids (FAHFAs), lipids with potent antidiabetic and anti-inflammatory activities, indicates

62 ed class of endogenous mammalian lipids with antidiabetic and anti-inflammatory effects.

63 The antidiabetic and antiatherosclerotic effects of adiponec

64 macrophages (MacT3) to analyze its potential antidiabetic and antiatherosclerotic effects.

65 11 might play important roles in metformin's antidiabetic and anticancer effects.

66 wo congeners 70 and 90 exhibiting consistent antidiabetic and antidyslipidemic activities were also p

67 The intervention comprised withdrawal of antidiabetic and antihypertensive drugs, total diet repl

68 Adiponectin, a WAT-derived hormone that has antidiabetic and antiinflammatory capabilities, increase

69 ydroxy stearic acids (PAHSAs) are endogenous antidiabetic and antiinflammatory lipids.

70 iabetic obese patients with pioglitazone, an antidiabetic and antiinflammatory PPARgamma agonist, res

71 be converted to NO in vivo and demonstrates antidiabetic and antiobesity properties in rodents.

72 lomic analysis revealed presence of multiple antidiabetic and antioxidant compounds.

73 e present study was undertaken to assess the antidiabetic and antioxidant potentials, polyphenolic pr

74 onectin is an adipocyte-derived hormone with antidiabetic and insulin-sensitizing properties.

75 ogenic acid (a polyphenol) and metformin (an antidiabetic and possible longevity promoting drug).

76 ting drugs, such as estrogen-like compounds, antidiabetics and sirolimus/rapamycin.

77 lopram (an antidepressant), troglitazone (an antidiabetic), and enilconazole (a fungicide).

78 pic adipokine that exerts anti-inflammatory, antidiabetic, and antiatherogenic effects through its re

79 fects, such as anticancer, hepatoprotective, antidiabetic, anti-inflammatory and antibacterial activi

80 ological effects, among them, antimicrobial, antidiabetic, antioxidative, antiobesity and antihyperte

81 ding analgesic, anti-inflammatory, anti-HIV, antidiabetic, antitumor, and antimicrobial.

82 of carbasugar SGLT2 inhibitors as potential antidiabetic/antitumor agents.

83 in-vitro antioxidant, anti-inflammatory and antidiabetic assays revealed for Z. spina-christi and Z.

84 general health and survival together with an antidiabetic benefit.

85 reatment with AMPK activators, including the antidiabetic biguanide metformin, inhibited FXR agonist

86 they reduced use of heart failure drugs and antidiabetics by 12.9% and 13.4%, respectively.

87 (SGLT-2) inhibitors have emerged as a novel antidiabetic class of drugs that exert favourable result

88 if effective delivery of potentially active antidiabetic compound such a the organic vanadate peptid

89 samples obtained from patients treated with antidiabetic doses of metformin.

90 many bioactive natural products, such as the antidiabetic drug acarbose, the crop protectant validamy

91 ar IC(50) values, far lower than that of the antidiabetic drug acarbose.

92 The antidiabetic drug canagliflozin is reported to possess s

93 Metformin (Met) is an approved antidiabetic drug currently being explored for repurposi

94 ch, it represents a target for anticancer or antidiabetic drug development.

95 iciency) led us to repurpose the widely used antidiabetic drug empagliflozin, an inhibitor of the ren

96 agon-like peptide 1 (GLP-1) receptor via the antidiabetic drug exenatide led to improvements in both

97 The widely prescribed antidiabetic drug metformin and the glycolytic inhibitor

98 The antidiabetic drug metformin consistently had the highest

99 Treatment with the antidiabetic drug metformin during ovariectomy-induced w

100 The antidiabetic drug metformin exhibits both chemopreventiv

101 ment of pregnant p53d/d mice with either the antidiabetic drug metformin or the antioxidant resveratr

102 that activation of AMPK with the widely used antidiabetic drug metformin or with the AMP mimetic 5-am

103 The antidiabetic drug metformin suppressed insulin-induced h

104 n detail the effects of the most widely used antidiabetic drug metformin.

105 etabolic stress induced by starvation or the antidiabetic drug metformin.

106 ffective utilization of E. maxima as an oral antidiabetic drug or functional food ingredient with a p

107 We further show that the antidiabetic drug phenformin, which activates AMP kinase

108 debated for several years as to whether the antidiabetic drug pioglitazone increases the risk for bl

109 d ( approximately 10-fold) treatment, or the antidiabetic drug rosiglitazone, all known PPAR activato

110 key intermediate in the preparation of oral antidiabetic drug Saxagliptin is discussed with an empha

111 Explorations of apoA-I as a novel antidiabetic drug should extend to treatments of diabeti

112 high excretion rates, high quantities of the antidiabetic drug sitagliptin (STG) enter wastewater tre

113 Metformin is a widely used antidiabetic drug that exerts cardiovascular protective

114 eneration biguanide, is a commonly used oral antidiabetic drug that has been shown recently to stimul

115 r3 O(OCOEt)6 (OH2 )3 ](+) (A), a prospective antidiabetic drug that undergoes similar H2 O2 induced o

116 rently studied as a potential new target for antidiabetic drug therapy.

117 ntiation following exposure to BDE-47 or the antidiabetic drug troglitazone (TROG).

118 Metformin is the first-line antidiabetic drug with over 100 million users worldwide,

119 l-tolerated and Federal Drug Agency-approved antidiabetic drug, has positive effects on insulin resis

120 we tested the effects of metformin, an oral antidiabetic drug, in mice fed an HFD.

121 e, Lehraiki et al. report that metformin, an antidiabetic drug, inhibited melanogenesis, in vitro and

122 e first time demonstrate a novel role of the antidiabetic drug, metformin, in suppressing uveitis in

123 ed highly adaptable for the synthesis of the antidiabetic drug, sitagliptin, with a single carbon iso

124 tformin is the most commonly prescribed oral antidiabetic drug, with well-documented beneficial preve

125 prescribed other diabetes treatments (other antidiabetic drug-exposed group).

126 PD compared to 517 individuals in the other antidiabetic drug-exposed group.

127 for the commercial synthesis of Januvia, an antidiabetic drug.

128 f incretin-based drugs as compared with oral antidiabetic-drug combinations among patients with a his

129 drugs, as compared with those receiving oral antidiabetic-drug combinations, were estimated by means

130 Widely used antidiabetic drugs (GLP-1 receptor agonists and sulfonyl

131 f action is unique in that no other approved antidiabetic drugs act via this mechanism, and raises th

132 relationship between cumulative use of other antidiabetic drugs and either outcome.

133 These data demonstrate that two antidiabetic drugs exert opposite effects on the PepT1 t

134 monotherapy with monotherapies of other oral antidiabetic drugs for assessing its efficacy and safety

135 istration industry guidance for licensing of antidiabetic drugs greatly increased the number of cardi

136 with placebo, subcutaneous insulin, or oral antidiabetic drugs in people with type 1 or type 2 diabe

137 ibitors have been approved as a new class of antidiabetic drugs in type 2 diabetes mellitus, and stud

138 to the carboxylic acid group of the type II antidiabetic drugs nateglinide and meglitinide were synt

139 ibenclamide and tolbutamide, two widely used antidiabetic drugs of the sulfonylurea (SU) family, show

140 l/L who were being treated with diet or oral antidiabetic drugs or had a total daily insulin dose of

141 oup of hybrid nitric oxide-releasing type II antidiabetic drugs possessing a 1-(pyrrolidin-1-yl)diaze

142 This important NR complex is a target for antidiabetic drugs since it binds to DNA and functions a

143 The antidiabetic drugs sitagliptin and exenatide, which inhi

144 rational basis for the development of novel antidiabetic drugs targeting this class of receptors.

145 s help to further advance the development of antidiabetic drugs targeting this protein.

146 l can be gradually purged by the glitazones, antidiabetic drugs that are agonists of peroxisome proli

147 lar target of the thiazolidinedione class of antidiabetic drugs that has many side effects.

148 e defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS, when cancer cell

149 r has been further highlighted by reports of antidiabetic drugs treating or promoting cancer.

150 All other antidiabetic drugs were discontinued on admission.

151 e development of GPR119 agonists as new oral antidiabetic drugs will be discussed.

152 approach for the rational design of type II antidiabetic drugs with a reduced risk of contraindicate

153 he global epidemic in type 2 diabetes, novel antidiabetic drugs with increased efficacy and reduced s

154 of any insulin regimen (with or without oral antidiabetic drugs).

155 izes the anticancer drug paclitaxel, certain antidiabetic drugs, and endogenous substrates, including

156 Moreover, in subjects not taking oral antidiabetic drugs, baseline osteocalcin concentrations

157 s the next generation of insulin-sensitizing antidiabetic drugs, because the currently marketed PPARg

158 receptor for the thiazolidinedione class of antidiabetic drugs, controls mitochondrial network fragm

159 ts with uncontrolled type 2 diabetes on oral antidiabetic drugs, initial injectable therapy with IDeg

160 rompted us to investigate the effects of two antidiabetic drugs, rosiglitazone and metformin, on PepT

161 0 kg/m(2) or higher, on stable doses of oral antidiabetic drugs, were recruited from outpatient clini

162 Thiazolidinedione (TZD) antidiabetic drugs, which activate the peroxisome prolif

163 a genomic occupancy and patient responses to antidiabetic drugs, with implications for developing per

164 ared with commonly used combinations of oral antidiabetic drugs.

165 located 15kB upstream of SLC5A2, a target of antidiabetic drugs.

166 glycemia through daily dosing of one or more antidiabetic drugs.

167 pment of better and safer PPARgamma-mediated antidiabetic drugs.

168 e 2 diabetes inadequately controlled on oral antidiabetic drugs.

169 uately controlled on basal insulin plus oral antidiabetic drugs.

170 d suggest an approach for the development of antidiabetic drugs.

171 's disease compared to the use of other oral antidiabetic drugs.

172 merged as a major potential target for novel antidiabetic drugs.

173 rter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs.

174 1)R receptor agonist 2-MeS-ADP, as potential antidiabetic drugs.

175 te effects of the PPARgamma agonist class of antidiabetic drugs.

176 SKM G(q) signaling may prove useful as novel antidiabetic drugs.

177 ve useful for the development of efficacious antidiabetic drugs.

178 ere non-smokers, aged >/=40 years, and using antidiabetic drugs.

179 ated with basal insulin with or without oral antidiabetic drugs.

180 ed remission to a non-diabetic state and off antidiabetic drugs.

181 This antidiabetic effect cannot be attributed to leakage of F

182 he PVN is capable of mimicking the sustained antidiabetic effect elicited by icv FGF1, we microinject

183 y disease; however, the mechanism behind its antidiabetic effect has been unclear.

184 This antidiabetic effect is not secondary to weight loss, doe

185 and a number of cellular models to study the antidiabetic effect of ANC, a standardised anthocyanin-r

186 ts glucose production and mediates the early antidiabetic effect of bariatric surgery, and gut microb

187 n microbial related mechanism underlying the antidiabetic effect of BBR on T2D.

188 duction, and both are required for the rapid antidiabetic effect of duodenal jejunal bypass surgery.

189 i.v. glucose tolerance test showed that the antidiabetic effect of i.c.v. FGF19 was solely due to in

190 The antidiabetic effect of leptin has been postulated to occ

191 Thus, the mechanisms responsible for the antidiabetic effect of leptin remain poorly understood.

192 The antidiabetic effect of MTZ does not appear to be a funct

193 ealth and survival in addition to a moderate antidiabetic effect, and notably these pro-survival vers

194 pounds in coffee matrix may contribute to an antidiabetic effect.

195 ion in liver macrophages is required for the antidiabetic effect.

196 production of insulin was important for the antidiabetic effect.

197 ly, the search for new compounds with potent antidiabetic effects but fewer undesired effects is an a

198 ed the hypothesis that ranolazine exerts its antidiabetic effects by inhibiting glucagon release via

199 19 has previously been shown to exert potent antidiabetic effects in ob/ob mice.

200 Numerous studies have characterized the antidiabetic effects of adiponectin, yet the precise cel

201 Although the impressive antidiabetic effects of bariatric surgery have been show

202 llow safely potentiating the antiobesity and antidiabetic effects of currently available GLP-1R agoni

203 ulinotropic agents besides GLP mediating the antidiabetic effects of DPP-4 inhibition.

204 sveratrol raises questions about whether the antidiabetic effects of oral resveratrol can act directl

205 ipose tissue may be a key contributor to the antidiabetic effects of this anion.

206 tes, but the underlying mechanisms for these antidiabetic effects remain elusive.

207 ng beige/brite cells exhibit antiobesity and antidiabetic effects, nitrate may be an effective means

208 ucrose diet (HFHSD) mice to characterize its antidiabetic effects.

209 sive, anorexic, analgesic, antibacterial and antidiabetic effects.

210 e bioactive lipids with antiinflammatory and antidiabetic effects.

211 FGF1 at a dose one-tenth of that needed for antidiabetic efficacy following peripheral injection ind

212 owth factor (FGF) receptors, we explored the antidiabetic efficacy of centrally administered FGF1, wh

213 ly, SPPARgammaMs regulated the expression of antidiabetic efficacy-associated genes to a greater exte

214 n experimentally or clinically substantiated antidiabetic functional plant foods and potatoes.

215 nalyses of this novel candidate leanness and antidiabetic gene.

216 or gamma (PPAR) agonist medications, such as antidiabetic glitazone (GTZ) drugs, are neuroprotective

217 diates the vascular protection observed with antidiabetic glitazones.

218 howed efficacy comparable to liraglutide, an antidiabetic GLP-1 analogue that carries a long-chain fa

219 There is concern that antidiabetic incretin-based drugs, including dipeptidyl

220 453 trials assessing 21 antidiabetic interventions from 9 drug classes were incl

221 to reduce HCC risk when compared with other antidiabetic interventions.

222 earic acid (PAHSA) are anti-inflammatory and antidiabetic lipokines that connect glucose and lipid me

223 k remains to be done to fully understand the antidiabetic mechanisms of leptin.

224 In this study, we investigated novel antidiabetic MEDICA analogues consisting of methyl-subst

225 ing 784 available human gut metagenomes, how antidiabetic medication confounds these results, and ana

226 ed PC, we examined the effect of duration of antidiabetic medication exposure after PC diagnosis on a

227 Antidiabetic medication exposure was not independently a

228 Antidiabetic medication may modify the incidence of hepa

229 s for prediabetes or type 2 diabetes; or (3) antidiabetic medication order.

230 : OR, 0.449; 95% CI, 0.357-0.566), and other antidiabetic medication use (RYGB: OR, 0.747; 95% CI, 0.

231 tes mellitus (30%) based on medical history, antidiabetic medication use, and glycated hemoglobin lev

232 Preoperative use of antidiabetic medication, coupled with an incretin agonis

233 ide 1 (GLP-1) agonist in addition to another antidiabetic medication, during the preoperative period.

234 egation inhibitors, and antihypertensive and antidiabetic medication.

235 outpatient diabetes diagnoses and 1 or more antidiabetic medications (sensitivity, 92.4%; positive p

236 f 102 genes in pathways targeted by marketed antidiabetic medications and applied Gene Set Enrichment

237 diabetes and cancer, the effects of various antidiabetic medications on cancer incidence and mortali

238 l and clinical data regarding the effects of antidiabetic medications on cancer incidence and mortali

239 e needed to further elucidate the effects of antidiabetic medications on cancer incidence and progres

240 data on laboratory results and dispensing of antidiabetic medications were extracted from electronic

241 oss, reduction in hemoglobin A1c, and use of antidiabetic medications, and very importantly a lower i

242 tem, drugs affecting the respiratory system, antidiabetic medications, drugs affecting the gastrointe

243 48 mmol/mol) after at least 2 months off all antidiabetic medications, from baseline to 12 months.

244 Existing antidiabetic medications, including SGLT-2 inhibitor tre

245 report that use of insulin, along with other antidiabetic medications, significantly diminished overa

246 lerance tests, hemoglobin A1C levels, and/or antidiabetic medications.

247 e 2 diabetes (T2D) influence the response to antidiabetic medications.

248 initiating treatment with other second-line antidiabetic medications.

249 decade-long clinical usage of these drugs as antidiabetics now allows for evaluation of patient-orien

250 Significant reductions in use of antidiabetics occurred in both surgical groups.

251 tions, evaluating cardiovascular outcomes of antidiabetic or antiplatelet medications.

252 CSVR) were identified and are proposed to be antidiabetic peptides from Sardine pilchardus muscle.

253 The antioxidant, anti-inflammatory and antidiabetic potential of fortified cakes were significa

254 These suggest the antidiabetic potential of S. aqueum leaf extract and its

255 The present study evaluates the antidiabetic potential of the flavonoids, rutin and its

256 ioactive phytochemicals with antioxidant and antidiabetic potential.

257 pha-glucosidase inhibition, to explore their antidiabetic potential.

258 is a key feature to select plant foods with antidiabetic potential.

259 f their natural or synthetic origin, display antidiabetic properties due to enzyme inhibition (glycog

260 anadium compounds have been reported to have antidiabetic properties for more than a century.

261 The description of the antidiabetic properties of vanadium compounds is describ

262 date, numerous studies have reported on the antidiabetic properties of various plant extracts throug

263 kitul products have been reported for their antidiabetic properties, extracts radical scavenging act

264 nes), full agonists of PPARgamma with robust antidiabetic properties, which are confounded with signi

265 various phytochemicals with antioxidant and antidiabetic properties, which include mostly flavonoids

266 ion, and mounting evidence suggests HDL have antidiabetic properties.

267 ammatory, immunomodulatory, antioxidant, and antidiabetic properties.

268 nthocyanin from maqui berry, and studied its antidiabetic properties.

269 n T2DM via its putative cardioprotective and antidiabetic property.

270 We aimed to compare the use of different antidiabetic strategies and the incidence of HCC.

271 ate insulin secretion and are the targets of antidiabetic sulfonylureas.

272 ibition as a potential anti-inflammatory and antidiabetic target in obesity.

273 Hence, there remains an urgent need for antidiabetic therapeutic agents that can induce regenera

274 ite diagnosis of type 2 diabetes or received antidiabetic therapies during follow-up were classified

275 archically the best when compared with other antidiabetic therapies for the prevention of HCC.

276 ansporter 2 (SGLT2) inhibitors are effective antidiabetic therapies in patients with type 2 diabetes

277 Antidiabetic therapies might further improve outcomes in

278 Gamma (PPARgamma) is a classical target for antidiabetic therapies with thiazolidinedione compounds.

279 e metabolism during heart failure, including antidiabetic therapies, anti-inflammatory therapies, and

280 r antagonists (GRAs) have great potential as antidiabetic therapies, murine and human studies have ra

281 ell expansion may be key to developing novel antidiabetic therapies.

282 oduction and disposal, and a major target of antidiabetic therapies.

283 of the cardiovascular safety profile of new antidiabetic therapies.

284 ancreas (normoglycemia in the absence of any antidiabetic therapy) survivals were determined, and sev

285 y, dietary habits, physical activity, and/or antidiabetic therapy.

286 ts entry into the blood is proposed as novel antidiabetic therapy.

287 te differentiation and a canonical target of antidiabetic thiazolidinedione medications.

288 pport the notion that BAT may function as an antidiabetic tissue in humans.

289 BAT) has attracted scientific interest as an antidiabetic tissue owing to its ability to dissipate en

290 n per 1.73 m(2) or higher, and taking stable antidiabetic treatment and ACE inhibitors or ARBs, for a

291 lucose metabolism is an important target for antidiabetic treatment approaches.

292 on, defined as intensification of background antidiabetic treatment or the initiation of new glucose-

293 Antidiabetic treatment reduces severe periodontal damage

294 er the oxytocin system a potential target of antidiabetic treatment.

295 ,000 patient years in those prescribed other antidiabetic treatments (IRR 0.72, 95% confidence interv

296 Antidiabetic treatments aiming to reduce body weight are

297 ed individuals were matched to 120,373 other antidiabetic users.

298 ay be alleviated and dramatic enhancement of antidiabetic vanadium compounds may result.

299 Studies of antidiabetic vanadium compounds, specifically the organi

300 fruticosa, as structurally new and powerful antidiabetics with unprecedented effects for a dietary m

301 ntimicrobial, anti-inflammatory, anticancer, antidiabetic, wound healing, anti-HIV, anti-anxiety and